The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy
Authors:
- 11 October 2017
- journal article
- review article
- Published by Springer Nature in Science China Life Sciences
- Vol. 60 (10) , 1058-1064
Abstract
Cancer treatment in the past few years has been transformed by a new kind of therapy that targets the immune system instead of the cancer itself to reinvigorate antitumor immunity with astonishing results. However, primary and acquired resistance to this type of treatment, namely immune checkpoint blockade (ICB), continue to counter treatment efficacy. In many cases, resistance has been attributed to defective or chronically enhanced interferon signaling and/or upregulation of alternative immune checkpoints, including T-cell immunoglobulin mucin-3 (Tim-3) and its ligand galactin-9 (Gal-9). In this article, we briefly describe the current knowledge of common checkpoint resistance mechanisms, focusing on the Tim-3/Gal-9 pathway as an alternative checkpoint that holds great promise as another target for ICB.Keywords
This publication has 77 references indexed in Scilit:
- The chronicles of T-cell exhaustionNature, 2017
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint BlockadeCell, 2016
- Coinhibitory Pathways in Immunotherapy for CancerAnnual Review of Immunology, 2016
- Growing tumors induce a local STING dependent Type I IFN response in dendritic cellsInternational Journal of Cancer, 2016
- Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting CellsPLOS ONE, 2015
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1Nature Immunology, 2012
- Glycosylation, galectins and cellular signalingCurrent Opinion in Cell Biology, 2011
- The Protein Tyrosine Kinase Tec Regulates a CD44highCD62L− Th17 SubsetThe Journal of Immunology, 2010
- Attenuation of Th1 response through galectin‐9 and T‐cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD miceEuropean Journal of Immunology, 2009
- T Cell Immunoglobulin Mucin-3 Crystal Structure Reveals a Galectin-9-Independent Ligand-Binding SurfaceImmunity, 2007